InhibOx collaborates with Lauras AS to advance its drug discovery projects

Oxford, UK - August 2009

InhibOx has undertaken a lead optimization project with Lauras AS, a Norwegian biotechnology company, to help it advance its drug discovery pipeline. Starting from the existing SAR and available structural data, InhibOx used its proprietary virtual screening platform and expertise to derive structural and QSAR models which rationalized the activity of the known leads and identified novel compounds for synthesis. In addition to novelty, these new compounds offer other potential advantages over previously existing leads.

“InhibOx has helped redesign the company’s drug targeting programme, and suggested new lines of derivitization that have delivered compounds with the properties we wanted. The competence InhibOx provides and the quality of what they deliver is exceptional.”

Kjetil Tasken, Lauras VP R&D

For further information, please contact:
Paul Finn, CEO, Telephone +44 1865 262002